Zobrazeno 1 - 10
of 153
pro vyhledávání: '"Priti S Hegde"'
Autor:
Daniel R Zollinger, Elizabeth Rivers, Alexander Fine, Yanmei Huang, Joseph Son, Akshita Kalyan, Wren Gray, Golshid Baharian, Carly Hammond, Rosalyn Ram, Lindsay Ringman, Dina Hafez, Daniel Savel, Vipul Patel, Marc Dantone, Cui Guo, Merrida Childress, Chang Xu, Dorhyun Johng, Brett Wallden, Prapti Pokharel, William Camara, Priti S Hegde, Jason Hughes, Corey Carter, Nicole Davarpanah, Viraj Degaonkar, Pratyush Gupta, Sanjeev Mariathasan, Thomas Powles, Sean Ferree, Lucas Dennis, Amanda Young
Publikováno v:
PLoS ONE, Vol 19, Iss 5, p e0302129 (2024)
Emerging technologies focused on the detection and quantification of circulating tumor DNA (ctDNA) in blood show extensive potential for managing patient treatment decisions, informing risk of recurrence, and predicting response to therapy. Currently
Externí odkaz:
https://doaj.org/article/3fc28d0921b64f258d166f8cdf7339fa
Autor:
Namrata S Patil, Wei Zou, Simonetta Mocci, Alan Sandler, Marcus Ballinger, Susan Flynn, Marcin Kowanetz, Priti S Hegde
Publikováno v:
PLoS ONE, Vol 16, Iss 2, p e0246486 (2021)
PurposeOverall survival (OS) is the most significant endpoint for evaluation of treatment benefit with checkpoint inhibitors (CPI) in cancer. We evaluated serum C-reactive protein (CRP) in non-small cell lung cancer (NSCLC) trials with atezolizumab (
Externí odkaz:
https://doaj.org/article/3cd9ebe18a8747349ef4cac75da859ee
Autor:
Monika A Jarzabek, William R Proctor, Jennifer Vogt, Rupal Desai, Patrick Dicker, Gary Cain, Rajiv Raja, Jens Brodbeck, Dale Stevens, Eric P van der Stok, John W M Martens, Cornelis Verhoef, Priti S Hegde, Annette T Byrne, Jacqueline M Tarrant
Publikováno v:
PLoS ONE, Vol 13, Iss 6, p e0198099 (2018)
Drug-related sinusoidal dilatation (SD) is a common form of hepatotoxicity associated with oxaliplatin-based chemotherapy used prior to resection of colorectal liver metastases (CRLM). Recently, hepatic SD has also been associated with anti-delta lik
Externí odkaz:
https://doaj.org/article/fe0051c7ad654064b4d0da667c7b0515
Autor:
Smruthy Sivakumar, Jay A. Moore, Meagan Montesion, Radwa Sharaf, Douglas I. Lin, Caterina I. Colon, Zoe Fleischmann, Ericka M. Ebot, Justin Y. Newberg, Jennifer M. Mills, Priti S. Hegde, Quintin Pan, Afshin Dowlati, Garrett M. Frampton, Julien Sage, Christine M. Lovly
Publikováno v:
Cancer Discovery.
Small cell lung cancer (SCLC) is a recalcitrant neuroendocrine carcinoma with dismal survival outcomes. A major barrier in the field has been the relative paucity of human tumors studied. Here we provide an integrated analysis of 3,600 “real-world
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c05ffc741bc045cba648aff3c92b3f6
https://doi.org/10.1158/2159-8290.cd-22-0620
https://doi.org/10.1158/2159-8290.cd-22-0620
Autor:
Lee A. Albacker, Priti S. Hegde, Garrett M. Frampton, Brian M. Alexander, Naiyer A. Rizvi, Leah A. Comment, David Fabrizio, Gaurav Singal, Alan Braly, Jay A. Moore, Dean C. Pavlick, Ethan S. Sokol, Virginia Fisher, Gerald Li, Max Minker, Ameet Guria, Nora Sanchez, Radwa Sharaf, Dexter X. Jin, Karthikeyan Murugesan, Meagan Montesion
Somatic HLA-I LOH is associated with decreased durable clinical benefit and progression free survival in ICI-treated NSCLC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25ae8eba790bd7e6d70baa335276b460
https://doi.org/10.1158/2159-8290.22535725.v1
https://doi.org/10.1158/2159-8290.22535725.v1
Autor:
Lee A. Albacker, Priti S. Hegde, Garrett M. Frampton, Brian M. Alexander, Naiyer A. Rizvi, Leah A. Comment, David Fabrizio, Gaurav Singal, Alan Braly, Jay A. Moore, Dean C. Pavlick, Ethan S. Sokol, Virginia Fisher, Gerald Li, Max Minker, Ameet Guria, Nora Sanchez, Radwa Sharaf, Dexter X. Jin, Karthikeyan Murugesan, Meagan Montesion
Neoantigen presentation arises as a result of tumor-specific mutations and is a critical component of immune surveillance that can be abrogated by somatic LOH of the human leukocyte antigen class I (HLA-I) locus. To understand the role of HLA-I LOH i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e82d91644d24da5d493cb0d66e86e71
https://doi.org/10.1158/2159-8290.c.6547924.v1
https://doi.org/10.1158/2159-8290.c.6547924.v1
Autor:
Priti S. Hegde, Mark R. Lackner, Garret M. Hampton, Amy Peterson, Premal Patel, Robert L. Yauch, Mark Merchant, Kyra J. Cowan, Luciana Burton, Vaishali Parab, Congfen Li, Elicia Penuel
PDF file - 22K, Changes in shed Met do not correlate with changes in cHGF over the duration of the first cycle of onartuzumab administration in the Phase 1A study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::445d4f7af40273c1e9422fbfa7d4016e
https://doi.org/10.1158/1535-7163.22499679
https://doi.org/10.1158/1535-7163.22499679
Autor:
Lee A. Albacker, Priti S. Hegde, Garrett M. Frampton, Brian M. Alexander, Naiyer A. Rizvi, Leah A. Comment, David Fabrizio, Gaurav Singal, Alan Braly, Jay A. Moore, Dean C. Pavlick, Ethan S. Sokol, Virginia Fisher, Gerald Li, Max Minker, Ameet Guria, Nora Sanchez, Radwa Sharaf, Dexter X. Jin, Karthikeyan Murugesan, Meagan Montesion
Characteristics of patients in the real-world clinico-genomic cohort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d04d6516cd719ccacceafa013677769
https://doi.org/10.1158/2159-8290.22535713.v1
https://doi.org/10.1158/2159-8290.22535713.v1
Autor:
Priti S. Hegde, Mark R. Lackner, Garret M. Hampton, Amy Peterson, Premal Patel, Robert L. Yauch, Mark Merchant, Kyra J. Cowan, Luciana Burton, Vaishali Parab, Congfen Li, Elicia Penuel
PDF file - 24K, cHGF levels are stable over time and are not variable between screening (any time during visit -24 hours) and predose (Day 0).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::754e28d16bdf0548b4252eaebc7b8e2b
https://doi.org/10.1158/1535-7163.22499676
https://doi.org/10.1158/1535-7163.22499676
Autor:
Priti S. Hegde, Mark R. Lackner, Garret M. Hampton, Amy Peterson, Premal Patel, Robert L. Yauch, Mark Merchant, Kyra J. Cowan, Luciana Burton, Vaishali Parab, Congfen Li, Elicia Penuel
The objective of this study was to evaluate circulating hepatocyte growth factor (cHGF) as a pharmacodynamic biomarker of Met inhibition for onartuzumab (MetMAb, OA5D5v2) in a phase I trial in patients with advanced cancers and a phase II trial in no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d781b118706dbc3f4a33a170feef898
https://doi.org/10.1158/1535-7163.c.6536214
https://doi.org/10.1158/1535-7163.c.6536214